Pharmaceutical company · TEVA

Teva
clinical trial
pipeline

Registry checked

Published

Respiratory is the largest mapped primary therapeutic group, with 2 of 9 active trials. This ranking covers mapped groups only. TEV-56286 is linked to 3 distinct active studies, with 1 Phase 1, 2 Phase 2. TEV-53408 is linked to 2 distinct active studies, with 1 Phase 1, 1 Phase 2.

Phase 3 study NCT06052267 in Asthma lists estimated primary completion on 31 October 2026. Phase 3 study NCT06664619 in Asthma lists estimated primary completion on 2 November 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

9active trials
as lead sponsor
  • Phase 13
  • Phase 24
  • Phase 32
  • Phase 40
  • Phase not recorded0

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

30 Sept 2026 – 29 Oct 2026 · UTC

Recorded changes

95 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later by 17 days

2026-09-15 (estimated)2026-10-02 (actual)
15 Sept 202602 Oct 2026

A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease

NCT06807463 · ClinicalTrials.gov
Recorded by ComplyRx
09 Oct 2026
Registry last updated
09 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-09-300000000
2026-10-010000000
2026-10-020000000
2026-10-030000221
2026-10-040000000
2026-10-050000000
2026-10-061110031
2026-10-070000000
2026-10-081010021
2026-10-091100022
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
Type totals3220295 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

TEV-56286

Canonical investigational asset

3
Active trials
2
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 22
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy Volunteers · Multiple System Atrophy
Next primary completion
15 September 2027 · estimated
Open drug

TEV-53408

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Celiac Disease · Vitiligo
Next primary completion
Not reported
Open drug

Fluticasone Propionate/Albuterol Sulfate

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Asthma
Next primary completion
02 November 2026 · estimated
Open drug

TEV-56248

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Asthma
Next primary completion
31 October 2026 · estimated
Open drug

Duvakitug

Canonical investigational asset

1
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Colitis, Ulcerative · Crohn Disease
Next primary completion
Not reported
Open drug

TEV-56278

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 1
  • Phase 11
  • Phase 20
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced Solid Tumors
Next primary completion
Not reported
Open drug

9 of 9 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 9 of 9 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Teva trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
4 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
TEV-56248

NCT06052267

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 6 inspected observations were not displayed.

6 candidate observations · 0 shown · 0 recorded after primary completion · 6 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

6 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 30 Aug 2023 · actual
    Primary completion: 31 Oct 2026 · estimated
    Study completion: 31 Oct 2026 · estimated

    2021202220232024202520262027202820292030
    A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
    Fluticasone Propionate/Albuterol Sulfate

    NCT06664619

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    4 candidate observations · 3 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

    • status flip · Recorded 2026-10-06 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-10-06 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • pc date moved · Recorded 2026-10-06 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 12 Dec 2024 · actual
    Primary completion: 02 Nov 2026 · estimated
    Study completion: 02 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    TOPAS-MSA
    TEV-56286

    NCT06568237

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

    4 candidate observations · 2 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    2 inspected observations omitted. At most three verified observations are shown, not full history.

    • status flip · Recorded 2026-10-08 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
    • enrollment change · Recorded 2026-10-08 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 02 Oct 2024 · actual
    Primary completion: 15 Sept 2027 · estimated
    Study completion: 15 Sept 2027 · estimated

    2021202220232024202520262027202820292030
    An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
    TEV-56286

    NCT07197866

    Phase 2 · Recruiting

    Trial source and qualifications

    An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 30 Sept 2025 · actual
      Primary completion: 03 May 2029 · estimated
      Study completion: 17 May 2029 · estimated

      2021202220232024202520262027202820292030

      Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

      4 selected of 4 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 2 actual primary completions, 0 untyped primary completions, 0 past estimates, 0 outside the horizon, 0 contradictory dates.

      04 / Therapeutic focus

      Where the activity is

      2

      active trials in Respiratory

      Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

      Active trials by primary therapeutic area

      • Respiratory2 trials
      • Dermatology1 trials
      • Gastroenterology & Hepatology1 trials
      • Immunology & Inflammation1 trials
      • Oncology1 trials
      • Unmapped2 trials
      • Healthy volunteers1 trials

      Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

      06 / Related companies

      All companies
      S

      Sanofi

      Shared indexed programme context · 1 selected asset

      Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

      Sources, scope and methodology

      ClinicalTrials.gov lead-sponsor scope

      Canonical current-owner attribution covers 614 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Teva Pharmaceutical Industries Ltd.. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

      ClinicalTrials.gov

      Attribution coverage

      621 distinct registry candidates produced 614 accepted studies. 0 mapped to other owners, 7 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 4 unverified, 4 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

      Indexed enrichment

      601 scoped records have indexed enrichment and 13 do not. Missing enrichment does not remove a trial from cohort counts.

      Scope observation

      The successful attribution check completed at 2026-10-30T22:59:14.493Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 0515d33d673f070c9da563faa3f89bb6afa9f00242ebdc24058740cc07e81ad1.

      Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

      Dated canonical-attribution snapshot: 614 mapped lead-sponsored clinical studies across all statuses. 601 have indexed enrichment, 13 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

      Keep following
      what matters.

      Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

      Build your watch

      Choose what to track in the watch builder.